Kate Van Brunt

533 total citations
30 papers, 415 citations indexed

About

Kate Van Brunt is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kate Van Brunt has authored 30 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Kate Van Brunt's work include Diabetes Management and Research (14 papers), Diabetes Treatment and Management (13 papers) and Cystic Fibrosis Research Advances (8 papers). Kate Van Brunt is often cited by papers focused on Diabetes Management and Research (14 papers), Diabetes Treatment and Management (13 papers) and Cystic Fibrosis Research Advances (8 papers). Kate Van Brunt collaborates with scholars based in United States, United Kingdom and Australia. Kate Van Brunt's co-authors include Kristina S. Boye, Louis S. Matza, Andrew Palsgrove, Kimberly N. Walter, Aodán Tynan, Miao Yu, Glenn Matfin, Alan G. Zimmermann, Matthew Reaney and Mark Lakshmanan and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Obesity and Metabolism and Diabetes Research and Clinical Practice.

In The Last Decade

Kate Van Brunt

29 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kate Van Brunt United States	11	223	96	74	62	59	30	415
Andrew W. Hitchings United Kingdom	10	45 0.2×	98 1.0×	73 1.0×	82 1.3×	24 0.4×	27	318
György Rokszin Hungary	12	167 0.7×	59 0.6×	92 1.2×	57 0.9×	32 0.5×	52	402
Beth Mitchell United States	12	283 1.3×	50 0.5×	27 0.4×	105 1.7×	21 0.4×	43	426
Paulo Carita France	9	128 0.6×	21 0.2×	28 0.4×	35 0.6×	55 0.9×	23	350
Antonio Ramírez de Arellano Spain	12	177 0.8×	29 0.3×	33 0.4×	20 0.3×	43 0.7×	33	298
Tilenka Thynne Australia	10	138 0.6×	37 0.4×	39 0.5×	56 0.9×	20 0.3×	24	323
María L. Méndez Spain	11	93 0.4×	39 0.4×	54 0.7×	58 0.9×	13 0.2×	21	528
Chiara Veronesi Italy	10	80 0.4×	52 0.5×	13 0.2×	105 1.7×	44 0.7×	52	335
Juliette C. Thompson United Kingdom	11	78 0.3×	66 0.7×	49 0.7×	42 0.7×	26 0.4×	18	344
Jin Choi United States	10	93 0.4×	34 0.4×	32 0.4×	130 2.1×	29 0.5×	19	359

Countries citing papers authored by Kate Van Brunt

Since Specialization

Citations

This map shows the geographic impact of Kate Van Brunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Van Brunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Van Brunt more than expected).

Fields of papers citing papers by Kate Van Brunt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Van Brunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Van Brunt. The network helps show where Kate Van Brunt may publish in the future.

Co-authorship network of co-authors of Kate Van Brunt

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Van Brunt. A scholar is included among the top collaborators of Kate Van Brunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Van Brunt. Kate Van Brunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Engels, E., Helen B. Forrester, Verdiana Trappetti, et al.. (2025). Is Ultrahigh Dose Rate Critical for the Effectiveness of Microbeam Radiation Therapy in a Broad-Beam Combined Treatment?. Advances in Radiation Oncology. 11(2). 101949–101949.

Merlo, Christian A., Maral DerSarkissian, Lisa J. McGarry, et al.. (2024). EPS6.05 Clinical outcomes in concurrent elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treated vs. ineligible cohorts in the US Cystic Fibrosis Foundation Patient Registry (CFFPR) during COVID-19. Journal of Cystic Fibrosis. 23. S51–S51. 1 indexed citations

Engels, E., Helen B. Forrester, Kate Van Brunt, et al.. (2024). The Impact of Synchrotron Microbeam Radiation Therapy Combined With Broad Beam in a Preclinical Breast Cancer Model. Advances in Radiation Oncology. 10(1). 101680–101680. 2 indexed citations

Schechter, Michael S., Gerry Oster, Derek Weycker, et al.. (2023). Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis. Pulmonary Therapy. 9(4). 479–498. 6 indexed citations

Lee, Tim, Gregory S. Sawicki, Josje Altenburg, et al.. (2022). EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS. Journal of Cystic Fibrosis. 22(3). 402–406. 36 indexed citations

Fajac, Isabelle, Cori Daines, I. Durieu, et al.. (2022). Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 22(1). 119–123. 25 indexed citations

Sawicki, Gregory S., et al.. (2021). Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis. 21(1). 96–103. 8 indexed citations

Valentine, William J., Kate Van Brunt, Kristina S. Boye, & Richard F. Pollock. (2018). Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. Applied Health Economics and Health Policy. 16(3). 357–366. 4 indexed citations

Idris, Iskandar, et al.. (2018). The Trend of High-Dose Insulin Usage Among Patients with Diabetes in the UK: A Retrospective Study. Diabetes Therapy. 9(6). 2245–2257. 13 indexed citations

10.

Yu, Maria, et al.. (2017). Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics. 39(11). 2284–2295. 17 indexed citations

11.

Brunt, Kate Van, et al.. (2016). Behaviours, thoughts and perceptions around mealtime insulin usage and wastage among people with type 1 and type 2 diabetes mellitus: A cross-sectional survey study. Diabetes Research and Clinical Practice. 126. 30–42. 9 indexed citations

12.

Brunt, Kate Van, Bradley Curtis, T. Iványi, et al.. (2016). Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin. Diabetes Therapy. 7(4). 793–807. 4 indexed citations

13.

Eby, Elizabeth L., et al.. (2015). Insulin Dosing and Outcomes Among Commercially Insured Patients With Type 2 Diabetes in the United States. Clinical Therapeutics. 37(10). 2297–2308.e1. 7 indexed citations

14.

Saunders, Rhodri, et al.. (2015). Cost-Effectiveness of Rapid-Acting Analog Insulin for Type 1 Diabetes In The Uk Setting. Value in Health. 18(7). A610–A610. 2 indexed citations

15.

Lage, Maureen J., et al.. (2015). Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes. Clinical Interventions in Aging. 10. 991–991. 2 indexed citations

16.

Matfin, Glenn, et al.. (2015). Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes. Journal of Diabetes Science and Technology. 9(5). 1071–1079. 43 indexed citations

17.

Matza, Louis S., Karen Chung, Kate Van Brunt, et al.. (2013). Health state utilities for skeletal-related events secondary to bone metastases. The European Journal of Health Economics. 15(1). 7–18. 24 indexed citations

18.

Brunt, Kate Van, et al.. (2013). Insulin Use in Long Term Care Settings for Patients With Type 2 Diabetes Mellitus: A Systematic Review of the Literature. Journal of the American Medical Directors Association. 14(11). 809–816. 7 indexed citations

19.

Matza, Louis S., Lesley Fallowfield, Karen Chung, et al.. (2012). Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Supportive Care in Cancer. 20(4). 657–677. 14 indexed citations

20.

Boye, Kristina S., Louis S. Matza, Kimberly N. Walter, et al.. (2010). Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. The European Journal of Health Economics. 12(3). 219–230. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact